scroll down

About us — Zenitar

Zenitar was established in April 2019 A start-to-end innovative drug development company Focusing on oncology, autoimmunity and inflammatory diseases Three innovative drugs covering six indications on clinical trial phase I and phase II
  • 2019

    Established Date

  • 70+

    Scientists

  • 30+

    Patents

Learn more >> Learn more >>

  • 01

    Structural Biology Platform

    Structural Biology Platform

    Employs artificial intelligence and machine learning algorithms to accelerate the discovery and optimization of novel drug candidates.

    Learn more >> Learn more >>

  • 02

    AI-Driven Drug Design Platform

    AI-Driven Drug Design Platform

    Employs artificial intelligence and machine learning algorithms to accelerate the discovery and optimization of novel drug candidates.

    Learn more >> Learn more >>

  • 03

    Organoids Screening Platform

    Organoids Screening Platform

    Employs artificial intelligence and machine learning algorithms to accelerate the discovery and optimization of novel drug candidates.

    Learn more >> Learn more >>

  • 04

    Patient-Derived Tumor Model Screening Platform

    Patient-Derived Tumor Model Screening Platform

    Employs artificial intelligence and machine learning algorithms to accelerate the discovery and optimization of novel drug candidates.

    Learn more >> Learn more >>

Product Pipeline